Gene Editing / Gene Therapy Seminar Series
Chief Scientific Officer
Oxana is an accomplished R&D leader with a strong track record of discovering and developing first-in-class therapeutics for rare genetic diseases. She has served as Dyne’s chief scientific officer since June 2021 after joining Dyne as senior vice president, head of research in January 2020. Prior to joining Dyne, Oxana served as head of musculoskeletal and renal research in Sanofi’s rare disease and neurological unit, advancing a pipeline of drug candidates using multiple therapeutic modalities, including nucleic acids, proteins and small molecules. She is the author of numerous patents, invited reviews, editorials, book chapters and original research articles in major scientific journals. Oxana received her Ph.D. in genetics from Moscow Genetics Institute, followed by postdoctoral fellowship training in neuromuscular diseases at the Howard Hughes Medical Institute at the University of Iowa.
The Gene Editing / Gene Therapy Seminar Series features leading academic, translational, and investor speakers in e-talks through the summer and fall.